Newsletter | June 24, 2024

06.24.24 -- Biopharma Outsourcing Analogs: From Cars To Eggs

SPONSOR

Webinar - Driving CDMO Efficiency: The Power of Flexible Platforms and Digital Data Access

We’ll demonstrate how KBI Biopharma’s mammalian (SUREtechnology) and microbial (PUREplatform) expression platforms, combined with industry-leading analytical capabilities, accelerate the development and manufacturing of mAbs, multispecific Abs, ADCs, fusion proteins, and other recombinant therapeutic proteins. We’ll also showcase PROGRAMview, our cutting-edge digital data access tool, highlighting its role in enhancing data access and collaboration during process development. Register here.

FEATURED EDITORIAL

Biopharma Outsourcing Analogs: From Cars To Eggs

An experienced healthcare investor/consultant, and former biotech CEO, puts on his thinking cap to provide readers some intriguing insights into your development and manufacturing outsourcing, and overall business model for new drugs and therapies.

Balanced Sourcing Of Custom Media/Buffer Formulations, Part 2: The Case For Insourcing

In part 1 of this 2-part series, the authors discussed the case for outsourcing of custom media/buffer formulations. In this article, they discuss key considerations in the case for vertical integration, or insourcing.

INDUSTRY INSIGHTS

Predictive Modeling Of Viscosity Behavior Using Artificial Neural Networks

Discover a modeling approach employing artificial neural networks using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated mAbs.

The Latest Trends In The Prevention And Treatment Of Cervical Cancer

Unearth what immune checkpoint inhibitors are showing promise in treating cervical cancer and how advancements in these treatments paired with additional prevention strategies are improving patient outcomes.

Cell Line Development: The Linchpin In Biotherapeutic Development

Review key factors for building a reliable CLD strategy, and learn how the right CDMO can help you achieve the high quality, high yield, and speed needed to successfully bring a biologic to market.

Considerations For Successful Upstream Manufacturing Process Scale-Up

A CDMO’s ability to scale seamlessly between bioreactor sizes is critical when adopting a client’s manufacturing process.

Bacteria Media Optimization Using In Silico Strategies

Determining ideal media composition for a bacteria is critical because it fosters a satisfactory grow rate, allowing the bacteria to reach the required growth yield.

Scaling Up: Increasing Production Capacity While Reducing Costs

Medical device companies must meet the demand plan for their devices while managing production costs. Gain valuable insights for scaling up production capabilities efficiently and cost-effectively.

Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles

The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

SPONSOR

Webinar: Accelerating Drug Development for Biologics: Flexible and Fast DNA-to-IND Programs

Join us on July 8th with Lonza to explore innovative strategies and good practices to accelerate the pathway to clinic, increase specific productivity, and enhance product yield. This session will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins. Click here to learn more.

SOLUTIONS

Analytical Assay Development And Qualification

By providing sensitive and accurate analytical data, analytics can help upstream development by performing spent media analysis or downstream purification by analyzing protein products.

Be A Gain Changer, 2x Throughput, Only With Supor Prime

Engineered to deliver the high throughput capacity of high-value drug products, Cytiva Supor™ Prime filters minimize product loss and waste, guaranteeing optimal yield. Watch to learn more about these innovative filters.

Scale Your Vaccine With Path-To-PAD

Our Vaccine Path-To-PAD program provides a clear and easy path to maximize yields at the beginning of development, with deep expertise in vaccines, robust expression platforms, and high-quality Vero and Quail cell lines.

End-to-End Services In Vaccines, CGTs, And Biologics

IDT Biologika provides end-to-end services in contract development and manufacturing of vaccines, cell & gene therapeutics, and fill-finish of biologics.

OUTSOURCED PHARMA CAPACITY UPDATE

Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: